Biotechnology & Medical Research

Page 2

Transgenomic Inc announces resignation of Chairman - Form 8-K

Tuesday, 23 Dec 2014 06:04am EST

Transgenomic Inc:Says on Dec. 18, Rodney S. Markin resigns from Board including from his position as Chairman, and from all committee memberships, effective as of Dec. 31.

Narhex Life Sciences Ltd gives H1 2015 guidance

Monday, 22 Dec 2014 09:56pm EST

Narhex Life Sciences Ltd:Says that it is currently experiencing sturdy growth in earnings for H1 2015 to its internal forecast, and expected to finish H1 2015 well above last year, with double digit growth.Expects H1 2015 revenue to finish with consistent growth in double digits.

Narhex Life Sciences Ltd announces issue of shares

Monday, 22 Dec 2014 09:32pm EST

Narhex Life Sciences Ltd:Issues 110,000,000 fully paid ordinary shares at an issue price of $0.005 per share.Funds raised will be used for working capital and costs associated with re-compliance with Chapters 1 & 2 of ASX Listing Rules.

Lion Biotechnologies announces closing of underwritten common stock offering

Monday, 22 Dec 2014 04:01pm EST

Lion Biotechnologies:Closes its underwritten offering of 6,000,000 shares of its common stock at $5.75 per share.Including 782,608 shares sold pursuant to the exercise in full of underwriters' option to purchase additional shares, resulting in gross proceeds from the offering of $34.5 mln before deducting underwriting discounts and commissions and offering expenses payable by Lion.Jefferies LLC and Cowen and Company, LLC acted as joint book-running managers and Trout Capital LLC acted as co-manager for the offering.

Kite Pharma submits investigational new drug application for Phase 1/2 Trial of KTE-C19, Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy

Monday, 22 Dec 2014 12:40pm EST

Kite Pharma Inc:Announces that the company has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to conduct a Phase 1/2 study of KTE-C19, for the treatment of patients with refractory aggressive non-Hodgkin lymphoma.KTE-C19 is Kite Pharma's lead product candidate in which a patient's T cells are genetically modified using a gammaretroviral vector to express a chimeric antigen receptor (CAR) designed to target the antigen CD19.

Jaguar Animal Health, Inc initiates filing of first new Animal Drug application with FDA

Monday, 22 Dec 2014 10:52am EST

Jaguar Animal Health, Inc:Says that it has initiated the filing of the Company's first New Animal Drug Application (NADA) with the U.S. Food and Drug Administration.Filing was submitted for Jaguar's Canalevia prescription drug candidate, a proposed minor-use minor-species (MUMS) drug for use in dogs undergoing chemotherapy.

Qiagen Marseille receives offer from management team to acquire some of its assets

Monday, 22 Dec 2014 10:32am EST

Qiagen Marseille SA:Receives offer from its management team to acquire some of its assets.Members of executive committee offer to buy all company's assets except intellectual property and employees.Offer made in context of creation of new company called HalioDx.Board decides to enter into exclusive negotiations with HalioDx.Company to retain intellectual property and make money through licensing agreements with the Qiagen group.HalioDx would sign partnership agreements with Qiagen Marseille and Qiagen concerning research and development and blood cancer.In the context of the operation Qiagen NV would launch public tender offer followed by squeeze-out for shares in Qiagen Marseille at 13.80 euros ($17) per share.

Qiagen Marseille receives offer from management team to acquire some of its assets; Qiagen NV to launch public tender offer

Monday, 22 Dec 2014 10:32am EST

Qiagen Marseille SA:Receives offer from its management team to acquire some of its assets.Members of executive committee offer to buy all company's assets except intellectual property and employees.Offer made in context of creation of new company called HalioDx.Board decides to enter into exclusive negotiations with HalioDx.Company to retain intellectual property and make money through licensing agreements with the Qiagen group.HalioDx would sign partnership agreements with Qiagen Marseille and Qiagen concerning research and development and blood cancer.In the context of the operation Qiagen NV would launch public tender offer followed by squeeze-out for shares in Qiagen Marseille at 13.80 euros ($17) per share.

Vascular Biogenics Ltd announces positive Phase 2a Data for VB-111 in Recurrent Thyroid Cancer

Monday, 22 Dec 2014 08:30am EST

Vascular Biogenics Ltd:Says positive results from its exploratory Phase 2a study of VB-111 in patients with recurrent, iodine-resistant differentiated thyroid cancer.VB-111 demonstrated disease stabilization and safety in the study, which was designed to assess the compound's safety and signal of efficacy.

Synthetic Biologics announces positive topline results from phase 1a trial of syn-004 for the prevention of C. Difficile Infection

Monday, 22 Dec 2014 06:58am EST

Synthetic Biologics Inc:Says positive topline safety and tolerability results from a Phase 1a clinical trial of SYN-004, the Company's investigational oral beta-lactamase enzyme for the prevention of Clostridium difficile (C. difficile) infection.

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Analyst Research

Report Title Price
Provider: Thomson Reuters StreetEvents
$75.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.